• Immediately Positions Gilead as a Leader in Cell Therapy
• Kite’s Lead CAR T Therapy Candidate, Axicabtagene Ciloleucel, Under Priority Review in the U.S. and Expedited Review in the EU
• Provides Broad Pipeline in Hematologic Malignances and Solid Tumors and Robust Platform for Continued Innovation
• Leverages Gilead’s Expertise in Rapidly Advancing Therapies to Address Unmet Patient Needs 

FOSTER CITY, Calif. & SANTA MONICA, Calif. – (BUSINESS WIRE) – Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc. (Nasdaq: KITE) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in cash. The transaction, which values Kite at approximately $11.9 billion, was unanimously approved by both the Gilead and Kite Boards of Directors and is anticipated to close in the fourth quarter of 2017. The transaction will provide opportunities for diversification of revenues, and is expected to be neutral to earnings by year three and accretive thereafter.